Pilot of IMPACT Intervention at the University of New Mexico (IMPACT)
Improving Healthcare Outcomes in American Indian and Hispanic Transplant Recipients Using Culturally-Tailored Novel Technology (IMPACT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Received kidney transplant at UNMH
- Greater than 18 years of age
- Mentally competent
Exclusion Criteria:
- Children under the age of 18
- Incarcerated patients
- Pregnant women
- Active systemic infection
- Non-skin malignancy or melanoma in the past 2 years
- Known cognitive impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IMPACT Intervention
Incorporate a rehabilitation approach to slowly increasing KT recipients' physical activity in addition to individualized dietary intervention at every post-transplant appointment through six months post-transplant, with follow-up at 12 months post-transplant.
|
IMPACT Intervention
|
|
Other: Usual Care
No exercise or diet specialization.
|
No exercise or diet specialization.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention Acceptability: Satisfaction
Time Frame: 12 months
|
Client Satisfaction Questionnaire, rated 1-4, where higher satisfaction will indicate greater intervention acceptability
|
12 months
|
|
Intervention Acceptability: Usability
Time Frame: 12 months
|
System Usability Scale, rated 1-5, where higher scores indicate ease of usability
|
12 months
|
|
Intervention feasibility: Retention
Time Frame: Through study completion, an average of 1 year
|
Retention rates
|
Through study completion, an average of 1 year
|
|
Intervention feasibility: Missing data
Time Frame: Through study completion, an average of 1 year
|
Estimates of the expected rates of missing data
|
Through study completion, an average of 1 year
|
|
Intervention feasibility: Attrition
Time Frame: Through study completion, an average of 1 year
|
Participant attrition will be measured by counting participants who do not continue with the study
|
Through study completion, an average of 1 year
|
|
Intervention feasibility: Participation
Time Frame: Through study completion, an average of 1 year
|
Time required for study participation during every intervention session
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medical records outcomes: Weight
Time Frame: Through study completion, an average of 1 year
|
Percent weight change
|
Through study completion, an average of 1 year
|
|
Medical records outcomes: Lipids
Time Frame: Through study completion, an average of 1 year
|
Total cholesterol: Less than 200 mg/dL, LDL: Less than 100 mg/dL, HDL: 60 mg/dL or higher, Triglycerides: less than 150 mg/dL
|
Through study completion, an average of 1 year
|
|
Medical records outcomes: HbA1c
Time Frame: Through study completion, an average of 1 year
|
HbA1c
|
Through study completion, an average of 1 year
|
|
Patient reported outcomes: Sleep
Time Frame: Baseline, 1 year
|
Pittsburgh Sleep Quality Index will measure different aspects of sleep and becomes one composite score, where lower scores denote a healthier sleep quality
|
Baseline, 1 year
|
|
Patient reported outcomes: QOL
Time Frame: Baseline, 1 year
|
We will use the PROMIS Scale v1.2 Global Health measure to assess quality of life (QOL), which includes items relevant to patients with kidney disease, including overall health, physical limitations, work, pain, energy, and emotional problems.
|
Baseline, 1 year
|
|
Patient reported outcomes: Occupational
Time Frame: Baseline, 1 year
|
Occupational Functioning Subscale: CHART-SF rated 0-100, where higher scores indicate greater levels of participation
|
Baseline, 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Larissa Myaskovsky, PhD, University of New Mexico
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 19-413 IMPACT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Replacement
-
NCT06445205SuspendedUtilising Volumetric Absorptive Microsampling (VAMS) Technology to Monitor Tacrolimus and CreatinineKidney Transplant Rejection | Kidney Replacement
-
NCT06374095Active, not recruitingKidney Replacement
-
NCT03965559CompletedKidney Transplant Rejection | Kidney Replacement | Plasmapheresis
-
NCT06925776Recruiting
-
NCT01276392WithdrawnKidney Replacement Disorder
-
NCT07477210Active, not recruitingHemodialysis | Peritoneal Dialysis (PD) | Kidney Replacement Therapy
-
NCT07437677Not yet recruitingHemodialysis | Transition | Peritoneal Dialysis (PD) | Kidney Replacement Therapy
-
NCT07262320RecruitingAKI | Acute Kidney Injury | Renal Replacement Therapy | Dialysis | Renal Replacement Therapy for Acute Kidney Injury in ICU | Critically Ill Acute Kidney Injury
-
NCT03836742CompletedAcute Kidney Injury | Renal Replacement Therapy | Acute Kidney Failure | Hemofiltration
Clinical Trials on Exercise and diet
-
NCT01343238Completed
-
NCT04132739TerminatedDiabetes | Frailty | Senior Syndrome
-
NCT00461994CompletedPediatric Obesity
-
NCT01554735CompletedQuality of Life | Inflammation | Sexual Dysfunction | Endothelial Dysfunction
-
NCT06113484Active, not recruitingCardiovascular Disease Risk
-
NCT00737152Unknown